Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma (Q38730550)

5 September 2017

title

Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma (English)

1 reference

5 September 2017

main subject

multiple drug resistance

1 reference

1 reference

Y Qin

1 reference

5 September 2017

S Zhang

1 reference

5 September 2017

S Deng

1 reference

5 September 2017

G An

1 reference

5 September 2017

X Qin

1 reference

5 September 2017

F Li

1 reference

5 September 2017

Y Xu

1 reference

5 September 2017

M Hao

1 reference

5 September 2017

Y Yang

1 reference

5 September 2017

W Zhou

1 reference

5 September 2017

H Chang

1 reference

5 September 2017

L Qiu

1 reference

5 September 2017

publication date

18 November 2016

1 reference

5 September 2017

1 reference

5 September 2017

1 reference

5 September 2017

1 reference

5 September 2017

page(s)

1123-1135

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

5 September 2017

1 reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Epigenetic inactivation of the MIR34B/C in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

MethPrimer: designing primers for methylation PCRs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Epigenetic silencing of miR-137 is a frequent event in gastric carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

The genetic architecture of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Clinical implication of centrosome amplification in plasma cell neoplasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Targeting aurora kinases as therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

c-Src/Histone Deacetylase 3 Interaction Is Crucial for Hepatocyte Growth Factor Dependent Decrease of CXCR4 Expression in Highly Invasive Breast Tumor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

7 January 2021

1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

7 January 2021

Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

7 January 2021

Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

7 January 2021

Roles of Aurora kinases in mitosis and tumorigenesis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

7 January 2021

A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.325

7 January 2021

Identifiers

DOI

10.1038/LEU.2016.325

1 reference

Dimensions Publication ID

5 September 2017

1002732802

0 references

1 reference